Tejara Capital Ltd Increases Position in Integra LifeSciences Holdings Corporation $IART

Tejara Capital Ltd lifted its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 42.6% in the 4th quarter, Holdings Channel reports. The firm owned 171,813 shares of the life sciences company’s stock after purchasing an additional 51,300 shares during the quarter. Tejara Capital Ltd’s holdings in Integra LifeSciences were worth $2,134,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in Integra LifeSciences by 3.8% in the third quarter. Amalgamated Bank now owns 19,809 shares of the life sciences company’s stock valued at $284,000 after buying an additional 728 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Integra LifeSciences by 6.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 14,200 shares of the life sciences company’s stock valued at $205,000 after purchasing an additional 848 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares in the last quarter. Finally, Capital Fund Management S.A. grew its holdings in Integra LifeSciences by 5.7% in the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock valued at $535,000 after purchasing an additional 1,997 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $14.50 on Friday. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The business has a fifty day moving average of $10.52 and a 200-day moving average of $11.65. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -2.24 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the company earned $0.41 earnings per share. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IART. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Citigroup raised their target price on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a report on Wednesday, May 6th. Wells Fargo & Company lifted their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and an average target price of $12.75.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.